Ursodeoxycholic acid-containing agent for treating or preventing presbyopia
US-11419880-B2 · Aug 23, 2022 · US
US2023040386A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2023040386-A1 |
| Application number | US-202217816812-A |
| Country | US |
| Kind code | A1 |
| Filing date | Aug 2, 2022 |
| Priority date | Dec 18, 2018 |
| Publication date | Feb 9, 2023 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.
Opening claim text (preview).
1 - 12 . (canceled) 13 . A method for treating or preventing presbyopia, comprising administering to a subject in need thereof an effective amount of ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof. 14 . The method according to claim 13 , wherein the ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof is administered ophthalmically. 15 . The method according to claim 13 , wherein the ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof is administered as an eye drop or an eye ointment. 16 . The method according to claim 15 , wherein the amount of ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof comprised in the eye drop or the eye ointment is 0.00001 to 10% (w/v). 17 . The method according to claim 13 , wherein the ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof is selected from ursodeoxycholic acid, tauroursodeoxycholic acid, glycoursodeoxycholic acid, ursodeoxycholic acid methyl ester, ursodeoxycholic acid ethyl ester, ursodeoxycholic acid n-propyl ester, ursodeoxycholic acid isopropyl ester, ursodeoxycholic acid n-butyl ester, ursodeoxycholic acid isobutyl ester, ursodeoxycholic acid sec-butyl ester, ursodeoxycholic acid tert-butyl ester, ursodeoxycholic acid n-pentyl ester, ursodeoxycholic acid n-hexyl ester, and a pharmaceutically acceptable salt thereof. 18 . The method according to claim 13 , wherein the ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof is selected from ursodeoxycholic acid, tauroursodeoxycholic acid, glycoursodeoxycholic acid, ursodeoxycholic acid methyl ester, ursodeoxycholic acid ethyl ester, ursodeoxycholic acid n-propyl ester, ursodeoxycholic acid isopropyl ester, and a pharmaceutically acceptable salt thereof. 19 . The method according to claim 13 , wherein the ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof is ursodeoxycholic acid or a sodium salt thereof. 20 . The method according to claim 15 , wherein the eye drop or the eye ointment comprises water, and an additive selected from ethyl pyruvate, sodium dihydrogenphosphate monohydrate, disodium hydrogenphosphate, hydroxypropyl methylcellulose, NaCl, and a mixture thereof. 21 . A method for treating or preventing an eye disease accompanied by a decrease in lens elasticity, comprising administering to a subject in need thereof an effective amount of ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof. 22 . A method for treating or preventing an eye disease accompanied by a decrease in accommodative function of the eye, comprising administering to a subject in need thereof an effective amount of ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.
Cellulose; Derivatives thereof · CPC title
Ophthalmic agents · CPC title
Inorganic compounds · CPC title
for accommodation disorders, e.g. myopia · CPC title
Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)} · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.